Incheon bio-healthcare startups conduct $90 million in US investment consultations

Six bio-healthcare startups from Incheon, South Korea, participated in the ‘RESI (Redefining Early Stage Investment) Boston 2026’ event in the United States. As part of the Incheon Startup Park ‘Boost Startup Program,’ the companies conducted approximately 60 business consultations totaling $90 million in potential scale.

Participating firms included N-Sage, Medisell Healthcare, Walk 101, WellPep, M-Tech Lab, and Kaimi. These companies engaged with major global entities such as AstraZeneca, Sanofi, AbbVie Ventures, and F-Prime Capital to discuss technology, business models, and investment opportunities. Specific discussions involved AI-based medical software, gene-editing technology, and next-generation antibiotics.